AI assistant
BioAge Labs, Inc. — Director's Dealing 2024
Sep 25, 2024
33722_dirs_2024-09-25_c0f205c3-8c7b-4528-892a-42328f43c652.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: BioAge Labs, Inc. (BIOA)
CIK: 0001709941
Period of Report: 2024-09-25
Reporting Person: GOLDSTEIN DOV A MD (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 22408 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.27 | 2031-12-15 | Common Stock (128331) | Direct | |
| Stock Option (Right to Buy) | $8.39 | 2034-04-16 | Common Stock (119587) | Direct |
Footnotes
F1: The option vested as to 1/4th of the total award on November 15, 2022, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.